CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
imatinib mesylate +2 moredrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓Histologically confirmed meningioma of any grade (benign, atypical, or malignant), including hemangiopericytoma
  • ✓Unequivocal evidence of tumor recurrence or progression by MRI or CT scan on stable steroid dosage (≥5 days)
  • ✓Evaluable residual disease by MRI or CT if previously treated with surgical resection
  • ✓Prior radiotherapy (external-beam, brachytherapy, or gamma-knife) allowed if disease has progressed since completion; progression must be confirmed by PET, thallium scan, MR spectroscopy, or surgery (not radiation necrosis)
Key exclusion· 8
  • ✕No bleeding disorders
  • ✕No deep venous or arterial thrombosis within the past 6 weeks
  • ✕No pulmonary embolism within the past 6 weeks
  • ✕No serious active infection

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00045734
NCT00045734Phase 2Completed
CompareCT.gov

Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma

National Cancer Institute (NCI)·interventional·Posted Jan 27, 2003·Updated May 15, 2017

In Brief

A Phase 2 clinical trial evaluating imatinib mesylate, laboratory biomarker analysis, and 1 other intervention for Adult Grade I Meningioma and 5 related conditions. Completed, enrolled 23 participants across 7 sites.

Detailed Summary

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Grade I Meningioma, Adult Grade II Meningioma, Adult Grade III Meningioma, Adult Meningeal Hemangiopericytoma, Adult Meningioma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2003
Enrollment StartFeb 1, 2003
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 23.4 years ago

Interventions

imatinib mesylatedrug

Given orally

laboratory biomarker analysisother

Correlative studies

pharmacological studyother

Correlative studies